Abstract:Quantitative or qualitative characterization of the drug-like features of known drugs may help medicinal and computational chemists to select higher quality drug leads from a huge pool of compounds and to improve the efficiency of drug design pipelines. For this purpose, the theoretical models for drug-likeness to discriminate between drug-like and non-drug-like based on molecular physicochemical properties and structural fingerprints were developed by using the naive Bayesian classification (NBC) and recursive partitioning (RP) techniques, and then the drug-likeness of the compounds from the Traditional Chinese Medicine Compound Database (TCMCD) was evaluated. First, the impact of molecular physicochemical properties and structural fingerprints on the prediction accuracy of drug-likeness was examined. We found that, compared with simple molecular properties, structural fingerprints were more essential for the accurate prediction of drug-likeness. Then, a variety of Bayesian classifiers were constructed by changing the ratio of drug-like to non-drug-like molecules and the size of the training set. The results indicate that the prediction accuracy of the Bayesian classifiers was closely related to the size and the degree of the balance of the training set. When a balanced training set was used, the best Bayesian classifier based on 21 physicochemical properties and the LCFP_6 fingerprint set yielded an overall leave-one-out (LOO) cross-validated accuracy of 91.4% for the 140,000 molecules in the training set and 90.9% for the 40,000 molecules in the test set. In addition, the RP classifiers with different maximum depth were constructed and compared with the Bayesian classifiers, and we found that the best Bayesian classifier outperformed the best RP model with respect to overall prediction accuracy. Moreover, the Bayesian classifier employing structural fingerprints highlights the important substructures favorable or unfavorable for drug-likeness, offering extra valuable information for getting high quality lead compounds in the early stage of the drug design/discovery process. Finally, the best Bayesian classifier was used to predict the drug-likeness of 33,961 compounds in TCMCD. Our calculations show that 59.37% of the molecules in TCMCD were identified as drug-like molecules, indicating that traditional Chinese medicines (TCMs) are therefore an excellent source of drug-like molecules. Furthermore, the important structural fingerprints in TCMCD were detected and analyzed. Considering that the pharmacology of TCMCD and MDDR (MDL Drug Data Report) was linked by the important common structural features, the potential pharmacology of the compounds in TCMCD may therefore be annotated by these important structural signatures identified from Bayesian analysis, which may be valuable to promote the development of TCMs.

Simulation-based comparison of Biopharmaceutics Classification System and drug structure

In Silico Modeling on ADME Properties of Natural Products: Classification Models for Blood-Brain Barrier Permeability, Its Application to Traditional Chinese Medicine and in Vitro Experimental Validation

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension

Estimation of ADME Properties with Substructure Pattern Recognition

Target Enhanced 2D Similarity Search by Using Explicit Biological Activity Annotations and Profiles

Exploring the Biologically Relevant Chemical Space for Drug Discovery

Identifying the Kind Behind SMILES-anatomical Therapeutic Chemical Classification Using Structure-Only Representations.

Quantitatively integrating molecular structure and bioactivity profile evidence into drug-target relationship analysis

Simg: an Alignment Based Method for Evaluating the Similarity of Small Molecules and Binding Sites

A novel strategy of coupling artificial intelligence with chemical fingerprinting to predict drug phase behaviors in complex systems

Drug-likeness Analysis of Traditional Chinese Medicines: Prediction of Drug-Likeness Using Machine Learning Approaches.

Introduction of Biopharmaceutics Classification System(bcs)and Its Application Progress

Classification Tree Model for Drug Penetrability Classification Identification of Biopharmaceutics Classification System

Revisiting Supersaturation of a Biopharmaceutical Classification System IIB Drug: Evaluation via a Multi-Cup Dissolution Approach and Molecular Dynamic Simulation

Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP

Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures

Coupling Drug Dissolution with BCS

[Research and development thought on biopharmaceutics classification system of Chinese materia medica].

Molecular Topology Analysis of the Differences Between Drugs, Clinical Candidate Compounds, and Bioactive Molecules

Bridging the Gap Between Molecular Descriptors and Mechanism: Cases Studies by Molecular Dynamics Simulations.